BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 10363992)

  • 1. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas.
    Ingvarsson S; Agnarsson BA; Sigbjornsdottir BI; Kononen J; Kallioniemi OP; Barkardottir RB; Kovatich AJ; Schwarting R; Hauck WW; Huebner K; McCue PA
    Cancer Res; 1999 Jun; 59(11):2682-9. PubMed ID: 10363992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
    Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
    Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
    Ahmadian M; Wistuba II; Fong KM; Behrens C; Kodagoda DR; Saboorian MH; Shay J; Tomlinson GE; Blum J; Minna JD; Gazdar AF
    Cancer Res; 1997 Sep; 57(17):3664-8. PubMed ID: 9288768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Fragile Histidine Triad gene and breast cancer.
    Yang Q; Yoshimura G; Sakurai T; Kakudo K
    Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival.
    Ingvarsson S; Sigbjornsdottir BI; Huiping C; Jonasson JG; Agnarsson BA
    Cancer Detect Prev; 2001; 25(3):292-8. PubMed ID: 11425271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers.
    Turner BC; Ottey M; Zimonjic DB; Potoczek M; Hauck WW; Pequignot E; Keck-Waggoner CL; Sevignani C; Aldaz CM; McCue PA; Palazzo J; Huebner K; Popescu NC
    Cancer Res; 2002 Jul; 62(14):4054-60. PubMed ID: 12124341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Loss of heterozygosity on chromosome 3p in breast cancer and precancerous lesion].
    Tang XL; Yao GY; Chen LR; Yang ZR; Li SL
    Zhonghua Wai Ke Za Zhi; 2006 Oct; 44(19):1314-7. PubMed ID: 17217815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of loss of heterozygosity in breast tumors from carriers of the BRCA2 999del5 mutation.
    Ingvarsson S; Geirsdottir EK; Johannesdottir G; Sigbjörnsdóttir BI; Eiriksdottir G; Ragnarsson G; Agnarsson BA; Gudmundsson J; Jonasson JG; Sigurdsson A; Egilsson V; Barkardottir RB
    Cancer Res; 1998 Oct; 58(19):4421-5. PubMed ID: 9766673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.
    Guler G; Uner A; Guler N; Han SY; Iliopoulos D; Hauck WW; McCue P; Huebner K
    Cancer; 2004 Apr; 100(8):1605-14. PubMed ID: 15073846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
    Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
    Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.
    Burke L; Khan MA; Freedman AN; Gemma A; Rusin M; Guinee DG; Bennett WP; Caporaso NE; Fleming MV; Travis WD; Colby TV; Trastek V; Pairolero PC; Tazelaar HD; Midthun DE; Liotta LA; Harris CC
    Cancer Res; 1998 Jun; 58(12):2533-6. PubMed ID: 9635574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic FHIT analysis in RER+ and RER- adenocarcinomas of the pancreas.
    Hilgers W; Groot Koerkamp B; Geradts J; Tang DJ; Yeo CJ; Hruban RH; Kern SE
    Genes Chromosomes Cancer; 2000 Mar; 27(3):239-43. PubMed ID: 10679912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FHIT gene and flanking region on chromosome 3p are subjected to extensive allelic loss in Egyptian breast cancer patients.
    Ismail HM; Medhat AM; Karim AM; Zakhary NI
    Mol Carcinog; 2011 Aug; 50(8):625-34. PubMed ID: 21557333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of heterozygosity on chromosomes 3, 9, 13, and 17, including the retinoblastoma locus, in uveal melanoma.
    Scholes AG; Liloglou T; Maloney P; Hagan S; Nunn J; Hiscott P; Damato BE; Grierson I; Field JK
    Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2472-7. PubMed ID: 11581185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent FHIT gene loss of heterozygosity in human papillomavirus-infected non-smoking female lung cancer in Taiwan.
    Wang J; Cheng YW; Wu DW; Chen JT; Chen CY; Chou MC; Lee H
    Cancer Lett; 2006 Apr; 235(1):18-25. PubMed ID: 15935551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Allelic loss and down-regulation of FHIT gene expression in esophageal squamous cell carcinoma].
    Liu FX; Huang XP; Zhao CX; Xu X; Han YL; Cai Y; Wu RL; Wu M; Zhan QM; Wang MR
    Ai Zheng; 2004 Sep; 23(9):992-8. PubMed ID: 15363189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma.
    Yang Q; Yoshimura G; Suzuma T; Tamaki T; Umemura T; Nakamura M; Nakamura Y; Wang X; Mori I; Sakurai T; Kakudo K
    Clin Cancer Res; 2001 Dec; 7(12):3869-73. PubMed ID: 11751477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA2 mutations in primary breast and ovarian cancers.
    Lancaster JM; Wooster R; Mangion J; Phelan CM; Cochran C; Gumbs C; Seal S; Barfoot R; Collins N; Bignell G; Patel S; Hamoudi R; Larsson C; Wiseman RW; Berchuck A; Iglehart JD; Marks JR; Ashworth A; Stratton MR; Futreal PA
    Nat Genet; 1996 Jun; 13(2):238-40. PubMed ID: 8640235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of FHIT function in lung cancer and preinvasive bronchial lesions.
    Sozzi G; Pastorino U; Moiraghi L; Tagliabue E; Pezzella F; Ghirelli C; Tornielli S; Sard L; Huebner K; Pierotti MA; Croce CM; Pilotti S
    Cancer Res; 1998 Nov; 58(22):5032-7. PubMed ID: 9823304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos.
    Nelson HH; Wiencke JK; Gunn L; Wain JC; Christiani DC; Kelsey KT
    Cancer Res; 1998 May; 58(9):1804-7. PubMed ID: 9581816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.